Venus Concept (NASDAQ:VERO) Releases Earnings Results

Venus Concept (NASDAQ:VERO) announced its earnings results on Thursday. The company reported ($12.14) earnings per share (EPS) for the quarter, FiscalAI reports. Venus Concept had a negative net margin of 68.77% and a negative return on equity of 871.77%. The company had revenue of $13.78 million during the quarter.

Venus Concept Trading Down 5.3%

Venus Concept stock traded down $0.10 during trading hours on Thursday, reaching $1.77. 142,276 shares of the company’s stock traded hands, compared to its average volume of 932,184. The firm’s 50 day moving average is $2.26 and its 200-day moving average is $2.38. The firm has a market capitalization of $2.52 million, a price-to-earnings ratio of -0.04 and a beta of 0.04. Venus Concept has a fifty-two week low of $1.68 and a fifty-two week high of $14.50. The company has a debt-to-equity ratio of 5.72, a quick ratio of 0.71 and a current ratio of 1.10.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Venus Concept in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Venus Concept

Venus Concept Inc, a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin.